# Sermorelin Research: GH/IGF-1, Aging, Sleep, and Cognition Findings

> Sermorelin research summarized: pediatric growth, reversal of age-related GH/IGF-1 decline, sleep and cognition signals, and the honest limits. Every figure cited.

Pediatric growth, the reversal of age-related GH/IGF-1 decline, sleep and cognition signals — and the points where adult anti-aging marketing outpaces the evidence.

## The short version

Sermorelin research has a strong, well-documented core and a softer, less-settled edge. The core: in growth-hormone-deficient children it accelerated growth, and in older men a two-week course pushed GH and IGF-1 back toward youthful levels. The edge: claims about fat loss, muscle gain, and anti-aging in healthy adults largely rest on a related, longer-acting analog (tesamorelin) rather than on sermorelin itself — and a major medical journal has explicitly called GH-secretagogue use for aging "not yet ready for prime time." This page keeps the proven findings and the open questions clearly apart.

## Does sermorelin work?

In the populations where it has been rigorously tested, the GHRH(1-29) signal is real and measurable. In prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) raised first-year height velocity from about 4.1 cm/year to roughly 7-8 cm/year — without excessive IGF-1 generation — in a multicenter trial [2]. In healthy old men (mean age 68), subcutaneous GHRH(1-29) at 0.5 mg and 1 mg twice daily for 14 days produced dose-related increases in 24-hour GH and IGF-1; after high-dose treatment, GH/IGF-1 parameters no longer differed from those of young men, with no effect on fasting glucose [6].

The honest qualifier is that adult anti-aging efficacy is far less established than these endpoints. An Annals of Internal Medicine editorial judged that using growth hormone secretagogues to prevent or treat the effects of aging is not yet justified by the evidence — "not yet ready for prime time" [5]. "Does it work" therefore has two answers: yes, for the specific GH/IGF-1 and pediatric-growth endpoints that were actually measured; not yet demonstrated, for the broad anti-aging promises attached to it in marketing.

## How long does it take for sermorelin to work, and will it raise IGF-1?

Acutely, a single dose elevates serum GH for roughly three hours despite rapid plasma clearance [3]. Measurable changes in the GH/IGF-1 axis in older men were reported over a 14-day course [6], and pediatric growth changes were assessed over the first year of therapy [2]. So the time course depends on the endpoint: a same-day GH pulse, a two-week shift in IGF-1, a first-year change in growth.

On IGF-1 specifically, GHRH(1-29) dosing raised IGF-1 in older men in a dose-related way, reaching values that no longer differed from young men at the high dose [6]. For scale, the related analog tesamorelin raised IGF-1 by 117% — within the physiologic range — in a controlled cognition trial [7]. That 117% figure is a tesamorelin result, reported here for context on the GHRH axis, not as a sermorelin-specific number.

## Sermorelin and tesamorelin: native fragment vs stabilized GHRH analog

The sermorelin vs tesamorelin question matters because much of the adult body-composition and cognition evidence in this field comes from tesamorelin — a stabilized synthetic GHRH analog — rather than from sermorelin itself, and keeping the two apart is essential to reading the record honestly. Sermorelin is the native GHRH(1-29) fragment; tesamorelin is an engineered, longer-lived GHRH analog approved (in a separate regulatory track) for HIV-associated lipodystrophy and frequently used in research as the GHRH-axis probe in adults.

In a randomized, double-blind, placebo-controlled trial of 152 older adults (66 with mild cognitive impairment), 20 weeks of daily subcutaneous tesamorelin (1 mg/day before bedtime) had a favorable effect on cognition (P=0.03), increased IGF-1 by 117% within the physiologic range, and reduced percent body fat by 7.4% [7]. These are tesamorelin outcomes. They illuminate what GHRH-axis stimulation can do, but they are not interchangeable with sermorelin's own evidence base — a distinction that popular summaries routinely blur.

## Does sermorelin burn fat, build muscle, or aid weight loss?

Pulsatile growth hormone contributes to lipolysis (fat breakdown), and GHRH-axis stimulation has produced body-composition changes — but the strongest of those data come from the stabilized analog tesamorelin (a 7.4% reduction in percent body fat in the cognition trial), not from sermorelin in healthy adults [7]. The body-composition evidence describes fat redistribution via the GH/IGF-1 axis; it does not amount to validated weight loss for sermorelin itself, and this is one of the points where marketing outpaces the evidence.

Muscle is similar. GH/IGF-1-axis modulation has been framed as a candidate strategy against age-related muscle loss, but the dealt sermorelin studies report GH and IGF-1 changes rather than direct muscle-mass outcomes — so muscle-building claims exceed the available sermorelin data. On testosterone: sermorelin acts on the GH/IGF-1 axis, not the gonadal axis, and the literature here documents GH and IGF-1 effects rather than any direct testosterone change.

## Does sermorelin affect sleep, the brain, and cognition?

GHRH has documented slow-wave-sleep-promoting effects in healthy men, which is one reason GHRH-axis dosing is studied at night — the peptide's action aligns with the deep-sleep window when GH is naturally secreted [1]. The cognition signal is carried mainly by the analog data: in the 152-person tesamorelin trial, 20 weeks of GHRH-analog dosing produced a favorable effect on cognition with executive-function improvement and the 117% IGF-1 rise within the physiologic range [7]. Beyond the somatotropic axis, GHRH administration has modulated brain signaling in analog trials, and a 2026 study reported that GHRH(1-44)NH2 promoted neuronal survival and attenuated amyloid-beta neurotoxicity in cell models, with a GHRH agonist reducing amyloid deposition in an Alzheimer's mouse model — hypothesis-generating preclinical signals, not approved sermorelin uses [13]. Human sermorelin-specific cognitive data remain limited.

## Sermorelin side effects and tolerability in the literature

Across the cited human studies, GHRH(1-29) was generally well tolerated. In the 14-day aging study, high-dose GHRH(1-29) reversed age-related GH/IGF-1 decline with no effect on fasting glucose [6]; in the 152-person GHRH-analog cognition trial, adverse events were characterized as mild [7]. The most-discussed theoretical concern is mechanistic rather than acute: because GH and IGF-1 are mitogenic (growth-promoting), chronically raising them is theorized to carry oncologic risk — a recognized safety consideration for any GH-axis intervention, even though sermorelin acts through the body's own feedback-regulated pulsatile secretion [1]. The dealt literature reports the favorable short-term tolerability and the mitogenicity caveat; long-term safety data specifically for adult anti-aging use remain limited [5].

## Is sermorelin safe? What the research reports

The studies report short-term tolerability rather than a verdict on long-term safety. In the trials cited here, GHRH(1-29) and the related GHRH analog were generally well tolerated, with adverse events described as mild and no fasting-glucose effect at the doses tested [6][7]. But authorities have been explicit that the evidence base for chronic, anti-aging use is not yet sufficient: the Annals of Internal Medicine editorial concluded GH-secretagogue use for aging is "not yet ready for prime time" [5], and the GH/IGF-1 mitogenicity question remains an open theoretical risk for any sustained GH-axis intervention [1]. "Is sermorelin safe" is therefore best answered as: tolerated in short studies, with long-term adult-use safety not yet established — and these pages describe research findings, not a recommendation to self-administer.

---

A near-monochrome instrument reading of the sermorelin record — the GHRH(1-29) pulse traced from receptor to IGF-1 and each figure logged to its study, the body-composition data attributed to tesamorelin where it belongs and the silence where the adult anti-aging evidence runs out left unfilled; no clinic behind the console and nothing here compounded, dosed, or sold.